These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 18178378)

  • 1. Monosodium glutamate (MSG): a villain and promoter of liver inflammation and dysplasia.
    Nakanishi Y; Tsuneyama K; Fujimoto M; Salunga TL; Nomoto K; An JL; Takano Y; Iizuka S; Nagata M; Suzuki W; Shimada T; Aburada M; Nakano M; Selmi C; Gershwin ME
    J Autoimmun; 2008; 30(1-2):42-50. PubMed ID: 18178378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neonatal monosodium glutamate treatment causes obesity, diabetes, and macrovesicular steatohepatitis with liver nodules in DIAR mice.
    Tsuneyama K; Nishida T; Baba H; Taira S; Fujimoto M; Nomoto K; Hayashi S; Miwa S; Nakajima T; Sutoh M; Oda E; Hokao R; Imura J
    J Gastroenterol Hepatol; 2014 Sep; 29(9):1736-43. PubMed ID: 24730643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of bezafibrate in nonalcoholic steatohepatitis model mice with monosodium glutamate-induced metabolic syndrome.
    Sasaki Y; Shimada T; Iizuka S; Suzuki W; Makihara H; Teraoka R; Tsuneyama K; Hokao R; Aburada M
    Eur J Pharmacol; 2011 Jul; 662(1-3):1-8. PubMed ID: 21549692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose dependent development of diabetes mellitus and non-alcoholic steatohepatitis in monosodium glutamate-induced obese mice.
    Sasaki Y; Suzuki W; Shimada T; Iizuka S; Nakamura S; Nagata M; Fujimoto M; Tsuneyama K; Hokao R; Miyamoto K; Aburada M
    Life Sci; 2009 Sep; 85(13-14):490-8. PubMed ID: 19683013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A dietary restriction influences the progression but not the initiation of MSG-Induced nonalcoholic steatohepatitis.
    Fujimoto M; Tsuneyama K; Nakanishi Y; Salunga TL; Nomoto K; Sasaki Y; Iizuka S; Nagata M; Suzuki W; Shimada T; Aburada M; Shimada Y; Gershwin ME; Selmi C
    J Med Food; 2014 Mar; 17(3):374-83. PubMed ID: 24588719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monosodium glutamate neonatal intoxication associated with obesity in adult stage is characterized by chronic inflammation and increased mRNA expression of peroxisome proliferator-activated receptors in mice.
    Roman-Ramos R; Almanza-Perez JC; Garcia-Macedo R; Blancas-Flores G; Fortis-Barrera A; Jasso EI; Garcia-Lorenzana M; Campos-Sepulveda AE; Cruz M; Alarcon-Aguilar FJ
    Basic Clin Pharmacol Toxicol; 2011 Jun; 108(6):406-13. PubMed ID: 21205225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early onset and progression of non-alcoholic fatty liver disease in young monosodium l-glutamate-induced obese mice.
    Coelho CFF; França LM; Nascimento JR; Dos Santos AM; Azevedo-Santos APS; Nascimento FRF; Paes AMA
    J Dev Orig Health Dis; 2019 Apr; 10(2):188-195. PubMed ID: 29855396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of polyphenol compounds melanin on NAFLD/NASH prevention.
    Belemets N; Kobyliak N; Virchenko O; Falalyeyeva T; Olena T; Bodnar P; Savchuk O; Galenova T; Caprnda M; Rodrigo L; Skladany L; Delev D; Opatrilova R; Kruzliak P; Beregova T; Ostapchenko L
    Biomed Pharmacother; 2017 Apr; 88():267-276. PubMed ID: 28110193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium alginate prevents progression of non-alcoholic steatohepatitis and liver carcinogenesis in obese and diabetic mice.
    Miyazaki T; Shirakami Y; Kubota M; Ideta T; Kochi T; Sakai H; Tanaka T; Moriwaki H; Shimizu M
    Oncotarget; 2016 Mar; 7(9):10448-58. PubMed ID: 26871288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH.
    Salomao M; Yu WM; Brown RS; Emond JC; Lefkowitch JH
    Am J Surg Pathol; 2010 Nov; 34(11):1630-6. PubMed ID: 20975341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of dietary monosodium glutamate on HFCS-induced hepatic steatosis: expression profiles in the liver and visceral fat.
    Collison KS; Maqbool ZM; Inglis AL; Makhoul NJ; Saleh SM; Bakheet RH; Al-Johi MA; Al-Rabiah RK; Zaidi MZ; Al-Mohanna FA
    Obesity (Silver Spring); 2010 Jun; 18(6):1122-34. PubMed ID: 20111022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with SRT1720, a SIRT1 activator, ameliorates fatty liver with reduced expression of lipogenic enzymes in MSG mice.
    Yamazaki Y; Usui I; Kanatani Y; Matsuya Y; Tsuneyama K; Fujisaka S; Bukhari A; Suzuki H; Senda S; Imanishi S; Hirata K; Ishiki M; Hayashi R; Urakaze M; Nemoto H; Kobayashi M; Tobe K
    Am J Physiol Endocrinol Metab; 2009 Nov; 297(5):E1179-86. PubMed ID: 19724016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonalcoholic fatty liver disease: from steatosis to cirrhosis.
    Farrell GC; Larter CZ
    Hepatology; 2006 Feb; 43(2 Suppl 1):S99-S112. PubMed ID: 16447287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis.
    Witek RP; Stone WC; Karaca FG; Syn WK; Pereira TA; Agboola KM; Omenetti A; Jung Y; Teaberry V; Choi SS; Guy CD; Pollard J; Charlton P; Diehl AM
    Hepatology; 2009 Nov; 50(5):1421-30. PubMed ID: 19676126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monosodium Glutamate (MSG)-Induced Animal Model of Type 2 Diabetes.
    Bahadoran Z; Mirmiran P; Ghasemi A
    Methods Mol Biol; 2019; 1916():49-65. PubMed ID: 30535681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous administration of monosodium glutamate to pregnant mice reduces weight gain in pups during lactation.
    Park JH; Choi TS
    Lab Anim; 2016 Apr; 50(2):94-9. PubMed ID: 26043886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term ingestion of monosodium L-glutamate did not induce obesity, dyslipidemia or insulin resistance: a two-generation study in mice.
    Nakamura H; Kawamata Y; Kuwahara T; Smriga M; Sakai R
    J Nutr Sci Vitaminol (Tokyo); 2013; 59(2):129-35. PubMed ID: 23727643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease.
    Liew PL; Lee WJ; Lee YC; Wang HH; Wang W; Lin YC
    Obes Surg; 2006 Dec; 16(12):1584-93. PubMed ID: 17217634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease.
    McCullough AJ
    Clin Liver Dis; 2004 Aug; 8(3):521-33, viii. PubMed ID: 15331061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
    Zou Y; Li J; Lu C; Wang J; Ge J; Huang Y; Zhang L; Wang Y
    Life Sci; 2006 Aug; 79(11):1100-7. PubMed ID: 16624332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.